Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- NXTD +21.7%, SHLO +14%, ASML +4.9%, MHG +3.6%, FAST +0.9%
M&A news:
- CLCD +32.7% (to be acquired by Eli Lilly (LLY) for $46.50/share)
Other news:
- APRI +22.5% (announces that Mexico has granted the co's commercialization partner, Ferring Pharmaceuticals, market approval for Vitaros)
- CRNT +9.7% (announces over $60 mln in new orders so far in 2017)
- LIFE +8.2% (FDA grants Fast Track Designation for aTyr's Resolaris to treat limb girdle muscular dystrophy 2b and removes partial clinical hold for resolaris)
- JAZZ +7.3% (FDA approves first generic version of Xyrem (sodium oxybate) Oral Solution, to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy, which is a potentially debilitating disease)
- GPOR +2.8% (reports Q4 net production averaged 787.0 MMcfe per day, +22% Y/Y)
- NTNX +1.5% (following Hewlett Packard Enterprise's purchase of hyperconverged infrastructure peer SimpliVity for $650 mln in cash)
- QCOM +1% (says will 'vigorously contest' FTC complaint)
Analyst comments:
- EDU +3.8% (upgraded to Overweight from Neutral at JP Morgan)
- DECK +2.5% (upgraded to Buy from Neutral at Buckingham Research)
- JWN +1.6% (upgraded to Outperform from Neutral at Credit Suisse)